Musculoskeletal & Connective Tissue Bioregulators

2 compounds · one is the other plus a proline

This is the smallest range on the site and the cleanest comparison in the whole bioregulator programme. Cartalax is Ala-Glu-Asp. Cortagen is Ala-Glu-Asp-Pro. One residue separates them, they are assigned to different tissues, and both are stocked here, which makes this the shortest route to testing whether the tissue-assignment claim survives contact with an assay.

Specification Table

The musculoskeletal and connective tissue range at a glance

Property	Value
Listings in this range	2
Compounds	Cartalax and Cortagen
Mass span	333.3 to 430.4 g/mol
Cartalax	Ala-Glu-Asp, 333.3 g/mol, 20mg lyophilised vial
Cortagen	Ala-Glu-Asp-Pro, 430.4 g/mol, 20mg metered nasal spray
Relationship	Cortagen is Cartalax with a terminal proline added
Shared opening	Ala-Glu-Asp, the same three residues in both
Storage	2-8°C, protected from light. Do not freeze
Page type	Category hub, not a product page
Schema page type	CollectionPage
Meta robots	index, follow
Regulatory status	No approved human formulation for either compound

What Does the Terminal Proline Change?

Proline is the only proteinogenic amino acid whose side chain loops back and bonds to its own backbone nitrogen. That ring restricts rotation at the peptide bond in front of it, so a terminal proline makes the C-terminus stiffer than any other residue would.

The practical consequence is enzymatic. Most carboxypeptidases work by fitting the terminal residue into a pocket and cleaving behind it, and a constrained proline fits that pocket poorly. Cortagen should therefore survive longer in the presence of serum peptidases than Cartalax does, purely as a matter of shape.

That is a testable prediction rather than a marketing claim, and it is the kind of thing a side-by-side stability run answers in an afternoon.

What Cartalax Peptide Dosage Figures Appear in Published Work?

Published figures for the Khavinson tripeptides cluster in the low milligram range per course rather than per administration, and the primary literature reports them in animal models rather than controlled human trials. Any figure quoted as a human dose for Cartalax is an extrapolation, and it is worth treating it as one.

For laboratory work the number that matters more is molar rather than mass. At 333.3 g/mol Cartalax delivers roughly 1.5 times the molar quantity per milligram that a 489 dalton tetrapeptide does, so matching two compounds by weight rather than by moles builds a systematic error into the comparison before the assay starts.

Why Is the Format Split Across These Two?

Cartalax ships as a lyophilised 20mg vial. Cortagen ships as a metered nasal spray at 20mg. Both sit far below the rough 1,000 dalton ceiling where nasal transport falls away, so the format split here reflects stocking rather than chemistry.

The vial gives control over concentration and the longer shelf life that dry powder brings. The spray fixes concentration at manufacture and starts the solution-state clock on the fill date. The wider peptide nasal spray range covers that trade in more detail, and the rest of the family sits under peptide bioregulators.

Frequently Asked Questions

Compliance Statement

Both products in this range are supplied for laboratory research use only. Neither is a drug, a supplement or a food, neither is intended for human or veterinary consumption, and neither may be used for diagnostic or therapeutic purposes. No compound listed here holds an approved human formulation. Purchasers are responsible for handling these materials in an appropriate research setting and in accordance with the regulations that apply to them.